Faria Nusrat

Faria Nusrat


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FNFaria Nusrat
Faria Nusrat
AKAkshay Khanna
Akshay Khanna
AJAditi Jain
Aditi Jain
WJWei Jiang
Wei Jiang
LHLavu Harish
Lavu Harish
ANAvinoam Nevler
Avinoam Nevler
The KRAS proto-oncogene is a major driver of pancreatic tumorigenesis and is nearly ubiquitously mutated in pancreatic ductal adenocarcinoma (PDAC). KRAS point mutations are detected in over 90% of PDAC cases, and these mutations have been shown to be associated with worse therapy response and overall survival. Pathogenic KRAS mutations are mostly limited to codons 12, 13 and 61, with G12D, G12V, G12R, Q61H, and G13D accounting for approximately 95% of the mutant cases. Emerging data have shown the importance of specific mutant subtypes, as well as KRAS variant allele frequency on clinical prognosis. Furthermore, novel technologies and therapies are being developed to target specific mutant subtypes, with encouraging early results. In this paper, we aim to review the recent studies regarding the relative impact of specific mutant KRAS subtypes on oncologic outcomes, the application of variant allele frequency in next generation sequencing analyses, and the ongoing research into therapies targeting specific mutant KRAS subtypes.

1 January 2024 in Dermatologic Therapy
Verified
Journal Article
Open access
JMJenna Mandel
Jenna Mandel
JMJaanvi Mehta
Jaanvi Mehta
RHRamsay Hafer
Ramsay Hafer
MAMahaa Ayub
Mahaa Ayub
FNFaria Nusrat
Faria Nusrat
NNNeda Nikbakht
Neda Nikbakht
There have been several reports of dupilumab use and the development of CTCL; however, the risk of CTCL development has not been adequately evaluated at the population level. The objective of this study is to determine whether dupilumab administration for AD is associated with an increased risk of developing CTCL and to identify at‐risk populations within this group. This retrospective cohort study used TriNetX, a deidentified medical record database including over 107 million patients, to identify eligible patients. Treatment and control groups were evaluated for the development of CTCL. Patients of any age with a documented diagnosis of AD were included. The treatment cohort included individuals treated with dupilumab, while the control cohort included AD patients treated with alternative therapies. Selected biologics were excluded from both groups. Subgroup analyses were performed to evaluate three age groups and to identify whether the risk of CTCL development was higher within a given time frame after starting dupilumab. We identified a total of 1,181,533 patients with AD. Of these, 19,612 patients were prescribed dupilumab. Both treatment and control groups included 19,612 patients matched for age, race, and sex. The mean age was 32.3 years (P = 0.96), and females accounted for approximately 52% (P = 0.93) in both groups. Patients treated with dupilumab for AD had an increased relative risk (RR) of developing CTCL compared to those never treated with dupilumab (RR = 4.59, 95% confidence interval 2.459–8.567, P < 0.0001). Subgroup analysis revealed that about half of the CTCL cases after dupilumab therapy (54.5%, 30/55) occurred in patients over the age of 60 years. In contrast, all CTCL cases (100%, 12/12) within the untreated cohort were observed in individuals over the age of 60. Of the patients diagnosed with CTCL following dupilumab use, the majority (62%, 34/55) were diagnosed within the first year. Overall, we find that the use of dupilumab for treating AD is associated with an increased relative risk of developing CTCL. This risk is highest in the first year of therapy and in adult patients. These findings suggest exercising caution in treating select groups of patients with dupilumab.

12 December 2025 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
FNFaria Nusrat
Faria Nusrat
KLKyle Lauck
Kyle Lauck
TJTara Jennings
Tara Jennings
NLNaomi Lawrence
Naomi Lawrence

14 October 2026 in JAAD Case Reports
Verified
Journal Article
Open access
FNFaria Nusrat
Faria Nusrat
KLKyle Lauck
Kyle Lauck
NLNaomi Lawrence
Naomi Lawrence
TJTara Jennings
Tara Jennings
LSLacy Sommer
Lacy Sommer